NOVO NORDISK A/S | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for NOVO NORDISK A/S

Sort by

Viewing results 1‒25 of 611

Disease control and prevention
Three health foundations tackle biggest disease threats in $300mn deal
...The foundation’s philanthropic firepower has surged thanks to sales of diabetes and weight loss drugs by Novo Nordisk, in which the foundation holds a controlling stake through its subsidiary Novo Holdings...
May 6, 2024
Novo Nordisk AS
Novo Nordisk chief seeks more deals to cement weight-loss lead amid ‘hype’
...Nordisk’s Wegovy, which imitates a hormone called GLP-1....
March 8, 2024
FT Live
Managing Operational Risk in M&A Transactions
Examining the value of business licensing and property tax in the deal cycle
Thursday, 20 JuneDigital Conference
Novo Nordisk AS
Novo to use Ozempic and Wegovy windfall to invest $7bn a year by 2030
...Kasim Kutay, Novo Holdings chief executive and a Novo Nordisk board member, told the Financial Times that rising income from its 28 per cent stake in Novo Nordisk and other investments would give his fund...
February 12, 2024
Drugs research
Novo Nordisk and Eli Lilly set to face new challenger in weight-loss race
...A number of celebrity endorsements and the success of Novo Nordisk and Eli Lilly’s treatments in helping users lose weight have made the drugs hugely popular, sparking supply shortages....
January 23, 2024
News in-depthNovo Nordisk AS
Novo Nordisk seeks to use obesity drug findings to prevent weight gain
...But she said if Novo Nordisk could develop such a treatment, it would be “ideal”....
December 5, 2023
Novo Nordisk AS
Novo Nordisk looks at flexible pricing for obesity drug
...He said Novo Nordisk was facing a “similar challenge” as some of the companies selling advanced therapies....
November 27, 2023
FT Live
Decarbonising India's Industries
Unlocking the technologies and capital required to accelerate progress
Tuesday, 11 JuneDigital Conference
Novo Nordisk AS
Novo Nordisk cuts price of weight loss drug Wegovy as competition heats up
...Novo Nordisk has been investing heavily in manufacturing capacity to meet soaring demand for Wegovy and Ozempic, which treats diabetes....
May 2, 2024
News updates from March 25: Boeing CEO to step down; UN Security Council calls for Gaza ceasefire
Novo Nordisk branches out with €1bn deal for heart disease therapies
...Novo Nordisk has struck a €1bn deal for Cardior Pharmaceuticals, a German biotech company developing RNA-based therapies to treat heart disease, as it seeks to build expertise in diseases beyond diabetes...
March 25, 2024
Novo Nordisk AS
Novo Nordisk in €1bn deal for RNA-based heart disease therapies
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
March 25, 2024
News updates from March 5: China targets 5% GDP growth in 2024, Gold and Bitcoin hit record highs
Ozempic cuts risk of kidney-related illness, Novo Nordisk study shows
...A new study by Novo Nordisk has shown that its blockbuster drug Ozempic cut the risk of death, disease progression and cardiovascular issues by 24 per cent for patients with type 2 diabetes and chronic kidney...
March 5, 2024
News updates from March 7: Sweden joins Nato; Powell says Fed ‘not far’ from having confidence to cut rates
Novo Nordisk shares hit fresh record with new weight loss pill results
...Novo Nordisk shares have hit a new record after the Danish drugmaker revealed early stage results for a new weight loss pill that offers better results than its blockbuster Wegovy....
March 7, 2024
News updates from January 31: Federal Reserve holds interest rates, EU commits €21bn in Ukraine military aid
Novo Nordisk’s market value reaches $500bn
...Novo Nordisk is the second-ever European company to achieve a $500bn market value following LVMH last April....
January 31, 2024
LexHelen Thomas
The Lex Newsletter: Living in an Ozempic world Premium content
...The awards ceremony prompted a rash of “the winner is . . . Ozempic” takes, referring to the diabetes and obesity medicine produced by Eli Lilly’s rival in the category, Novo Nordisk....
March 15, 2024
News in-depthEli Lilly & Co
Eli Lilly races to boost capacity as it rolls out rival to Novo Nordisk weight-loss drug
...However, the plants will not enable Novo Nordisk to ramp up production until 2026....
March 5, 2024
News updates from January 31: Federal Reserve holds interest rates, EU commits €21bn in Ukraine military aid
Novo Nordisk reports 36% jump in sales in 2023 powered by weight-loss drug
...Novo Nordisk’s blockbuster weight loss drugs powered the company to record a 36 per cent increase in sales last year....
January 31, 2024
FT Live
FTWeekend Festival: U.S. edition
The Saturday where the Financial Times Weekend paper comes to life
Saturday, 10 May 2025The REACH, at the Kennedy Center for the Performing Arts, F Street Northwest, Washington, DC, USA
Letter
Letter: Novo Nordisk is controlled by a charity and profitable!
...I don’t think shareholders of Novo Nordisk, now Europe’s most valuable company and celebrating a century of profitable growth, would agree....
February 2, 2024
Novo Nordisk AS
Novo Nordisk ‘surprised’ by high European demand for weight-loss drugs
...A Novo Nordisk trial published in November studied more than 17,600 people aged above 45 with obesity who had cardiovascular disease, but not diabetes, comparing Wegovy with a placebo....
February 4, 2024
Novo Nordisk AS
Novo Nordisk strikes $11bn deal to expand production of weight loss drug
...The success of Ozempic and Wegovy has delivered a windfall to Novo Holdings, which is paid a dividend by Novo Nordisk....
February 5, 2024
Novo Nordisk AS
Novo Nordisk shares hit record high as weight-loss drugs power profits
...Novo Nordisk shares hit a record high on Wednesday, as the Danish pharma group’s blockbuster weight-loss drugs powered a surge in sales and profits last year, cementing its position as Europe’s most valuable...
January 31, 2024
News in-depthDrugs research
The race to develop the next generation of weight-loss drugs
...In addition to the phase 3 study, Novo Nordisk has launched a head-to-head trial of Wegovy versus Zepbound....
April 1, 2024
Eli Lilly & Co
Eli Lilly calls for scrutiny of rival Novo Nordisk’s deal to expand production of weight-loss drug
...Surging demand for a new class of diabetes and weight-loss drugs has caused a huge jump in revenues at Novo Nordisk and Lilly, creating a market that could be worth about $100bn by the end of the decade,...
February 6, 2024
News updates from February 5: King Charles diagnosed with cancer, McDonald’s blames war on weak sales
Novo Holdings agrees to buy Catalent in $16.5bn deal
...Novo Holdings, the controlling shareholder in Novo Nordisk, has signed a $16.5bn deal to acquire US-based medicines manufacturer Catalent, in a deal that will bolster the Danish drugmaker’s supply chain....
February 5, 2024
The Big Read
FT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk
...It also ensured Novo Nordisk was not for sale. “So not even Elon Musk in a wild night could take over or attempt to take over Novo Nordisk,” he says....
December 19, 2023
Drugs research
Viking Therapeutics shares more than double on ‘statistically significant’ weight-loss trial results
...Like Novo Nordisk’s Wegovy and Ozempic, Viking’s VK2735 mimics the GLP-1 hormone that can suppress appetite....
February 27, 2024
Novo Nordisk AS
Novo Nordisk signs deals worth up to $1bn with US biotechs in race for obesity drugs
...The deals are the first signed under a collaboration between Novo Nordisk and Flagship Pioneering in May 2022....
January 4, 2024

Previous pagePage 1 of 25Next page